Ann Dermatol.  2022 Jun;34(3):173-181. 10.5021/ad.2022.34.3.173.

Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis

Affiliations
  • 1Department of Dermatology, Seoul National University Hospital, Seoul, Korea
  • 2Departments of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea
  • 3Departments of Biostatistics, SMG-SNU Boramae Medical Center, Seoul, Korea

Abstract

Background
With accumulating evidence that achieving a 90% improvement in the Psoriasis Area and Severity Index score (PASI90) has better correlation with improved healthrelated quality of life as compared to PASI75 achievement, there has been demand for establishing new treatment goals for psoriasis.
Objective
We investigated whether the short-term PASI90 achievement would predict longer drug survival as compared to PASI75 achievement.
Methods
This single-center retrospective cohort study reviewed 180 treatment series in 128 patients with plaque psoriasis, who were treated with tumor necrosis factor-alpha inhibitors (n=12), ustekinumab (n=88), secukinumab (n=23), guselkumab (n=45), and ixekizumab (n=12). The first effectiveness assessment, usually performed within 12 to 20 weeks, was considered a short-term treatment response to biologics.
Results
After adjustment for covariates, time-dependent Cox proportional hazards regression analysis showed that moderate responders (short-term achievement of ≥PASI75 but p=0.0220).
Conclusion
The short-term PASI90 achievement is a better predictor of longer drug survival as compared to PASI75 achievement.

Keyword

Biological products; Prognostic factor; Psoriasis; Survival analysis; Treatment outcome
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr